10-K · March 25, 2026
EDAP has realigned to focus exclusively on its Focal One HIFU platform and reports a string of regulatory wins (CE Mark March 26, 2025; FDA 510(k) Nov 20, 2025) and an expanding clinical evidence base (HIFI study: 3,328…
Earnings analysis · 10-Q
EDAP earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
EDAP TMS reported a total revenue of $17.8 million for Q1 2026, reflecting a significant 24.8% year-over-year increase, primarily driven by a 78.3% growth in their HIFU segment. However, the company reported a net loss…
Read full summary
EDAP TMS reported a total revenue of $17.8 million for Q1 2026, reflecting a significant 24.8% year-over-year increase, primarily driven by a 78.3% growth in their HIFU segment. However, the company reported a net loss of $9.1 million, wider than the previous year's loss of $7.4 million, highlighting ongoing operational challenges despite strong top-line growth.
Reported figures
- Earnings per share
- $-0.25
- Gross margin
- 45.73%
- Segment
- HIFU
- Segment
- ESWL
- Segment
- Distribution
What stood out
-
Significant Revenue Growth
Total revenue reached $17.8 million, a 24.8% increase from $14.3 million in Q1 2025.
-
HIFU Segment Explodes
HIFU revenues surged by 78.3%, rising from $6.5 million to $11.6 million year-over-year.
-
Improved Gross Margin
Gross margin improved to 45.7% from 42.0%, aided by higher sales of HIFU units.
-
Increased Cash Flow
Despite a net loss, operational cash flow improvements included positive working capital changes totaling $2.7 million.
-
Reduced Cost of Sales as Percentage of Revenue
Cost of sales fell to 54% of net sales from 58% a year prior, contributing to margin improvement.
-
Higher EPS Estimates Despite Losses
Despite an EPS loss of -$0.25, Q1 estimates showed improvements in revenue expectations.
What to watch
-
Increased Net Loss
Net loss grew to $9.1 million, compared to $7.4 million in the same quarter last year.
-
Operating Expenses Surge
Operating expenses rose by 26%, from $12.3 million to $15.5 million, resulting in wider operating losses.
-
Decline in Non-HIFU Revenue
Both ESWL and Distribution segments reported declines in revenue, with ESWL down 15.8% and Distribution down 21.2%.
Management's outlook
Revenue guidance for 2026 is reiterated at a target of $50.0 million to $54.0 million for the core HIFU business.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.